Abstract The deposition of the b-amyloid (Ab) peptide in senile plaques and cerebral Ab-amyloid angiopathy can be seeded in b-amyloid precursor protein (APP)-transgenic mice by the intracerebral infusion of brain extracts containing aggregated Ab. Previous studies of seeded b-amyloid induction have used relatively short incubation periods to dissociate seeded b-amyloid induction from endogenous b-amyloid deposition of the host, thus precluding the analysis of the impact of age and extended incubation periods on the instigation and spread of Ab lesions in brain. In the present study using R1.40 APPtransgenic mice (which do not develop endogenous Ab deposition up to 15 months of age) we show that: (1) seeding at 9 months of age does not induce more Ab deposition than seeding at 3 months of age, provided that the incubation period (6 months) is the same; and (2) very long-term (12 months) incubation after a focal application of the seed results in the emergence of Ab deposits throughout the forebrain. These findings indicate that the presence of Ab seeds, and not the age of the host per se, is critical to the initiation of Ab aggregation in the brain, and that Ab deposition, actuated in one brain area, eventually spreads throughout the brain.
Introduction
The deposition of b-amyloid (Ab) peptide in senile plaques and cerebral Ab angiopathy (CAA) can be induced in the brains of b-amyloid precursor protein (APP)-transgenic (tg) mice by the infusion of Ab-rich brain extracts from patients with Alzheimer's disease (AD) or from aged APPtg mice [5, 11, 18, 29] . Mechanistically, the seeding of Ab deposition resembles the transmission of prion disease in that a misfolded, multimeric form of the disease-associated protein appears to instigate aggregation by corruptive molecular templating [10, 25, 28] . Ab deposition also has been induced in wild-type marmosets [1, 22] , a nonhuman primate that produces human-type sequence Ab [9] .
Advancing age is the greatest risk factor for developing AD [21] , but how age promotes the development of Ab plaques and CAA remains uncertain [3] . Previous studies of the seeded induction of Ab deposition in mice have employed Tg2576 and APP23 mouse models that spontaneously form amyloid plaques and CAA beginning sometime around 8-10 months of age [11, 18] . To unambiguously identify the seeded Ab deposits in the absence of endogenous and spontaneously generated lesions, these studies typically used relatively short incubation periods of 3-6 months after intracerebral administration [5, 11, 16, 18] , and 6-7 months after intraperitoneal administration [6] . After longer periods, distinguishing seeded deposits from those that normally form in these models becomes increasingly problematic, thus hampering the analysis of the impact of advancing age and extended incubation periods on the instigation and spread of Ab lesions in the brain.
In the present study, we used a genomic, homozygous APP-tg mouse model (R1.40 mice) that begins to exhibit Ab deposition only in late adulthood [13] to examine (1) whether seeding is more effective when initiated in older animals, compared to younger animals, and (2) the longterm effects of focally administered Ab seeds on the evolution and spread of b-amyloid lesions in the brain.
Materials and methods

Mice
Male, hemizygous R1.40 APP-tg mice on a B6.129 background were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and bred with C57BL/6J mice. Homozygous mice were then generated by cross-breeding the hemizygous offspring. R1.40 mice carry a yeast artificial chromosome containing the genomic copy of human APP harboring the K670N-M671L mutation [15] . R1.40 APP-tg mice in the present study were homozygous and were maintained under specific pathogen-free conditions. The experimental procedures were carried out in accordance with the veterinary office regulations of BadenWürttemberg (Germany) and approved by the local Animal Care and Use Committees.
Preparation of brain extracts
Extracts were prepared from 22-to 25-month old, Abetadepositing APP23 mice (tg extract), or from age-matched, non-transgenic (wild-type [Wt]) mice (Wt extract) as previously described [18] . The forebrains were obtained and frozen on dry ice and stored at -80°C. Samples were homogenized at 10% (w/v) in PBS, vortexed, sonicated 3 9 5 s and centrifuged at 3,0009g for 5 min. The supernatant was used as the seeding agent. Ab levels were estimated with electrochemiluminescence-linked immunoassay, revealing Ab concentrations of 10-20 ng/ll.
Stereotaxic injection of brain extracts
Mice were anaesthetized with a mixture of fentanyl (0.05 mg/kg body weight), midazolam (5 mg/kg body weight) and medetomidine (0.50 mg/kg body weight). Bilateral stereotaxic injections of extract were made with a Hamilton syringe into the hippocampus (2.5 ll) and overlying neocortex (1.0 ll). Extract was injected into the hippocampus (AP -2.5 mm, L ±2.0 mm, DV -1.8 mm) over a 2-min period, and the needle was kept in place for an additional 2 min. The needle was raised to the overlying neocortex (AP -2.5 mm, L ±2.0 mm, DV -1.0 mm) and the additional 1 ll of extract was injected over a 1-min period. After 2 more minutes, the needle was slowly withdrawn before suturing. After surgery an antidote (flumazenil 0.5 mg/kg body weight, atipamezole 2.5 mg/kg body weight, naloxone 1.2 mg/kg body weight) was administered. A total of 38 mice were used (see figure captions for details). Two mice were excluded from the analysis because the injections missed the dorsal hippocampus; one mouse was excluded because of hydrocephalus; two mice were excluded due to lack of seeding. The excluded mice were dispersed over the experimental groups.
Tissue processing, histological and stereological analysis The mice were transcardially perfused with PBS under deep anesthesia (ketamine 400 mg/kg, xylazine 40 mg/kg). Brains were harvested, hemidissected, and the left hemispheres were processed as described [6] . The sections were immunostained using polyclonal antibody CN3 (1:1,000; raised against residues 1-16 of human Ab) [6] and visualized using standard immunoperoxidase procedures with the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA).
The areal density of Ab-immunoreactive lesions was quantitated in random-systematic sets of every 12th section through the neocortex and hippocampus. Pia-associated vessels were not counted. Stereological analysis of CN3-positive staining was performed using a Zeiss microscope equipped with a motorized x-y-z stage coupled to a videomicroscopy system and the Stereo Investigator software (MicroBrightField, Inc, Williston, VT, USA) as described [18] .
Adjacent sets of sections were stained with Congo red according to standard protocols and viewed under crosspolarized light and analyzed. The following additional antibodies were used: rabbit polyclonal antibody against cow glial fibrillary acidic protein (GFAP) (Dako, Glostrup, Denmark); rabbit polyclonal antibody against ionized calcium-binding adapter molecule 1 (Iba1) (Wako; Richmond, VA, USA).
Immunoblotting and electrochemiluminescence-linked immunoassay
The right hemisphere of PBS-perfused mice was homogenized at 10% w/v in buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA, and Complete Mini protease inhibitor cocktail [Roche Diagnostics GmbH, Penzberg, Germany]). To assess Ab and APP levels, 4-12% NuPage Bis-Tris mini gels using NuPage LDS sample buffer were used (Invitrogen, Carlsbad, CA, USA), followed by protein transfer onto nitrocellulose membranes and probing with antibody 6E10 (Covance, Princeton, NJ, USA). As an internal control, monoclonal anti-GAPDH antibody (Hy Test Ltd, Turku, Finland) was used. Densitometric values of band intensities were analyzed using ImageJ 1.44 (http://www.rsbweb.nih.gov/ij/).
Statistical analysis
All values are expressed as means ± SEMs. Statistical analyses were performed using SPSS 16.0 software (SPSS Japan, Tokyo, Japan) and Statview 5.0.1 (SAS Institute Inc., Cary, NC, USA), with the significance threshold set at p B 0.05, two tailed.
Results
Human APP expression and the quantity of human Ab were studied in the brains of R1.40 APP-tg mice at 3, 9, and 15 months of age. No significant differences among the three age groups were found (Fig. 1) . Immunohistochemical analysis did not detect any Ab deposits in the brains of the mice at 3 and 9 months, while in two of six 15-month-old mice, occasional Ab deposits were found in the frontal cortex (Fig. 1) .
To determine whether the age of the host is important for the seeded induction of b-amyloidosis, R1.40 APP-tg mice received injections of Ab-containing brain extracts (tg extract) or wild-type (Wt) extract into the hippocampus and overlying neocortex at 3 months of age and were analyzed at 9 months of age; a second group was seeded at 9 months of age and analyzed at 15 months of age (Fig. 2) . As an additional control to study the long-term effects of seeding, a third group was injected at 3 months of age and sacrificed at 15 months of age (Fig. 2) . The results revealed quantitatively similar induction of Ab deposition in the hippocampus and overlying neocortex of the tg extract-seeded mice in groups 1 and 2, i.e., the degree of seeding after a 6-month incubation period was similar whether the mice were infused at 3 months of age or at 9 months of age (Fig. 3) . In both groups, the amyloid was Congo red-negative and diffuse in nature. Wt extractinoculated controls did not show Ab induction (Fig. 3) .
When R1.40 APP-tg mice were intracerebrally injected with tg extract at 3 months of age and allowed to incubate for 12 months, extensive Ab deposition was apparent in the 15-month-old mice that exceeded the quantity of lesions after 6 months of incubation by approximately sixfold (Fig. 3) . Although most of the induced amyloid again was Congo red-negative, some of the Ab deposits in the vicinity of the injection site (dorsal hippocampus) were Congo redpositive and surrounded by darkly stained, GFAP-positive . Shown are immunoblots, using antibody 6E10, of three mice/age group; GAPDH served as a loading control. b Quantification of protein levels in all mice revealed no difference among the groups (one-way ANOVA for APP and Ab; both p [ 0.05). Three samples in each age group were applied to one gel, and two gels were used in total. Densitometric values of band intensities were analyzed using ImageJ 1.44, and percentages relative to the amount in 3-month-old mice were calculated from the average value at 3 months of age. c No Ab deposition was found in the brains of 3-and 9-month-old R1.40 mice by immunohistochemical analysis, while in two of six 15-month-old mice, infrequent Ab deposits were present in the frontal cortex. Scale bar 500 lm Fig. 2 Study design. Group 1 was intracerebrally seeded at 3 months of age, and analyzed at 9 months; group 2 was seeded at 9 months of age and analyzed at 15 months; group 3 was seeded at 3 months of age and analyzed at 15 months hypertrophic astrocytes and Iba1-positive enlarged microglia (Fig. 3) . Strikingly, in 12-month incubation mice, Ab deposition had spread throughout the entire neocortex and hippocampus, with additional deposition in the thalamus and septal nuclei, and was more widespread compared to that in the 6-month incubation groups (Fig. 4) . Both parenchymal and vessel-associated Ab deposits were observed (Fig. 4) .
Discussion
Previous studies have shown that brain-derived Ab aggregates can induce Ab lesions in the brains of susceptible mice [5, 6, 11, 16, 18, 29] . In the present study, we used the genomic-based R1.40 APP-tg model as host. These animals exhibit endogenous Ab deposition at approximately 15 months of age [13] , thus allowing for the analysis of extended incubation periods in Ab extractinoculated mice. Our results reveal that intracerebral injections of Ab-containing brain extract also induce Ab deposition in this model, although the Ab induction after a 6-month incubation period was less than that seen in APP23 mice after 4 months of incubation [16, 18] . This observation is consistent with the threefold overexpression of human APP in R1.40 mice compared to sevenfold overexpression in APP23 animals [15, 26] , and supports the view that the induction of Ab deposition is dependent on the concentration of Ab in the inoculum as well its production by the host [8, 18] .
We found that a 6-month incubation period induced similar levels of Ab aggregation in the brains of young (3 months) and older (9 months) R1.40 APP-tg mice, indicating that the aged brain does not provide a more favorable environment for the induction of Ab deposition once Ab seeds are present. Our results, while surprising in light of the view that age is a prominent risk factor for amyloid lesions [3, 7, 27] , may be attributed to the fact that the brain levels of Ab are constant in pre-depositing R1.40 mice between 3 and 15 months of age [17] . Unchanging Ab levels prior to Ab pathology also have been reported in other AD mouse models [12, 14] . These findings suggest that age may increase the risk of AD by impairing the ability of cells to dispose pathogenic seeds [2, 20] . In Fig. 3 Older mice and younger mice show similar levels of induced Ab deposition. However, long-incubation periods allow for generation of widespread Ab aggregation and glial cell response. a Induction of Ab deposition was evident in all three groups of R1.40 mice that were intracerebrally seeded with the tg extract, but not with the Wt extract. While the b-amyloid induction was similar in groups 1 and 2, Ab load was the greatest in group 3. Adjacent sections were doublestained with Congo red and GFAP or Iba-1. While in groups 1 and 2, all induced b-amyloid was Congo red-negative, group 3 showed at least some Congo red-positive deposits surrounded by darkly stained and hypertrophic GFAP-positive astrocytes (inset, left) and Iba1-positive microglia (inset, 23 ; p \ 0.001) and subsequent Scheffé post hoc analyses were used to pinpoint group differences (*p \ 0.05, **p \ 0.01, ***p \ 0.001). Scale bar 500 and 10 lm addition, it cannot be excluded that a similar experiment in which seeding is compared in a young host versus a host at an age closer to the end of its mean life span would yield different results.
The most striking finding to emerge from the inoculations in R1.40 mice was the presence of Ab deposits in much of the forebrain after the 12 month incubation period. Previous work has shown that the focal infusion of Ab seeds into the hippocampus is sufficient to induce Ab deposition throughout the entire hippocampus and even in connected brain areas; however, induction of lesions in widespread regions of the forebrain has not been previously observed [5, 10] . The mechanism of this extensive spreading of Ab deposition is not clear, but implies that seeds not only migrate within brain structures and along defined neuronal pathways, but also may disseminate along perivascular fluid drainage channels, by vascular transport, or by simple diffusion through the brain parenchyma [10] . The recent finding that small, soluble Ab species are particularly potent inducers of b-amyloidosis [16] , similar to the strong infectivity of small, non-fibrillar prion particles [24] , underscores potential mechanistic similarities in the induction and spread of Ab and PrP aggregates in the brain.
Birefringence under crossed-polarizing filters is indicative of the amyloid-like nature of proteinaceous deposits after staining with the dye Congo red [30] . In seeded R1.40 APP-tg mice, the duration of the incubation period influenced the degree to which the resulting Ab deposits were congophilic. Whereas the 6-month incubation period, starting at either 3 or 9 months of age, did not result in the induction of congophilic lesions, Congo red-positive plaques were observed after the 12-month incubation period. However, congophilic deposits were only observed near the injection site, indicating that diffuse pathology occurs first and eventually develops into Congo red-positive (i.e., amyloid) plaques. Because the cytological changes associated with Ab deposition are most strongly associated with amyloid per se [4] rather than with diffuse deposits, the lack of congophilic amyloid induction after the 6-month incubation period did not allow us to determine whether the amyloid-associated cytopathology (neuritic dystrophy and glial activation) differs between young (9 months) and older (15 months) hosts [3, 7] .
From a translational perspective, the present findings support the widely held notion that therapies directed at mitigating the formation of Ab pathology should begin early in the pathogenic cascade that leads to AD [19, 23] . The exposure to Ab seeds profoundly influences the onset and degree of b-amyloid pathology in APP-tg mouse models. While there is not yet direct evidence that exogenous seeds are involved in the initiation of AD, it is likely that endogenously generated seeds become increasingly prevalent with age due to the decline of proteostatic Fig. 4 Longer incubation times result in extensive spreading of Ab deposition in the forebrain. a Twelve months after intracerebral injections of the tg extract, copious Ab was deposited in the brain (shown are coronal sections of the mouse presented in Fig. 3 ; the coordinates from bregma AP are indicated). Note that Ab deposition was widespread throughout the neocortex and hippocampus, although tg extract was injected only locally into the hippocampus and overlying cortex at AP -2.5 mm. b Ab load in each section from anterior to posterior is shown for the 12-month incubation mice (group 3) and compared to the 6-month incubation mice (groups 1 and 2) (section 1 to section 11 approximate location from bregma AP is as follows, section 1 AP ?2.2 mm, section 5 AP ?0.1 mm, section 8 AP -1.8 mm, section 11 AP -3.3 mm). Note that the induced Ab is the highest around the injection site (corresponding to sections 9 and 10) in all groups, and that the Ab deposits have spread throughout the brain, including the most anterior parts. Scale bar 500 lm processes [3, 20] . The neutralization or removal of endogenous Ab seeds thus remains a promising but elusive therapeutic goal for interfering with the pathogenesis of AD.
